Sudeep Pharma delivered a confident debut on the Indian stock exchanges on 28 November 2025, marking a notable entry into the public markets. The company’s shares opened significantly higher than the issue price, reflecting strong investor interest and the enthusiasm observed during the IPO bidding phase.
The stock listed at ₹733.95 on the BSE and ₹730 on the NSE, compared with the issue price of ₹593. This reflects a listing premium of 23.76% on the BSE and 23.10% on the NSE. The robust start mirrors the exceptional response during the IPO, which raised ₹895 crore through a mix of fresh issuance and an offer for sale.
Subscription Highlights
The IPO saw remarkable demand, closing with an overall subscription of 93.71 times.
- QIB investors led the response at 213.08 times.
- NIIs followed at 116.72 times.
- Retail investors subscribed to their portion 15.65 times.
This extensive participation reflects broad confidence in the company’s position in the global excipients and speciality nutrition ingredients market.
Business Overview
Sudeep Pharma is a major producer of:
- Pharmaceutical excipients
- Food-grade minerals
- Speciality nutrition ingredients
The company supplies to over 100 countries and operates six manufacturing facilities with a combined annual capacity of 50,000 MT. Its portfolio includes more than 200 specialised products, spanning calcium, magnesium, potassium, zinc, iron, and sodium ingredients. These solutions are used extensively in pharmaceuticals, nutraceuticals, food processing, and speciality nutrition products.
Sudeep Pharma has built strong in-house R&D capabilities supported by laboratories and pilot plants focused on mineral salts and ingredient innovation. It also maintains long-standing relationships with global pharmaceutical and nutrition brands.
Financial Performance
The company reported steady growth in FY25:
- Revenue: ₹511.33 crore, up 10% from FY24
- Net Profit: ₹138.69 crore, slightly higher than the previous year
- EBITDA Margin: 39.7%
- PAT Margin: 27.6%
These numbers highlight consistent profitability and efficient operations within a high-entry-barrier industry.
Use of IPO Proceeds
From the fresh issue component, Sudeep Pharma plans to allocate ₹75.8 crore towards capital expenditure for acquiring machinery at its Nandesari Facility 1 in Gujarat. The remaining funds will be directed towards general corporate purposes.
Industry Outlook
India’s food and nutritional ingredients market is expanding steadily. The broader ingredients sector, valued at $22 billion in 2024, is projected to grow to $32 billion by 2029, driven by rising health awareness and disposable incomes. The vitamins and minerals segment is expected to see similar momentum, growing from $2.1 billion to $3 billion during the same period.
Sudeep Pharma’s established capabilities, global reach, and technology-driven processes place it in a favourable position to benefit from these long-term trends.
People Also Read:
- Excelsoft Technologies IPO: Shares List at a 12.5% Premium on NSE & BSE
- Capillary Technologies IPO: Shares List Marginally Lower at ₹571.90 on NSE
- Fujiyama Power Systems IPO: Shares Make Weak Market Debut, List at 4% Discount
- Tenneco Clean Air IPO Listing: Strong Market Debut with 27% Premium
- Emmvee Photovoltaic IPO: Shares Make Muted Market Debut, List Flat At ₹217
Conclusion
Sudeep Pharma’s strong listing highlights the confidence investors have in its industry leadership, expansive product portfolio and global reach. With its well-established manufacturing base, consistent financial performance, and ongoing capacity expansion, the company has entered the public markets on a firm footing.
If you are exploring more investment opportunities, check out our dedicated page on upcoming IPO listings to stay updated on the latest market offerings.
